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INTRODUCTION
Immunoglobulin-E (IgE)-mediated allergic diseases, in
particular allergic asthma, are mediated primarily by Th2
lymphocytes (1). Th1 and Th2 cells reciprocally regulate each
other through the cytokines they secrete (1, 2). Association
of allergic disorders with the Th2 cytokine pattern raises the
possibility to design prophylactic and therapeutic modali-
ties in a way that would promote Th1 immune response and
thereby down-regulate the Th2 immune response (2, 3).
Mycobacteria are among the most potent inducers of Th1
response (4, 5). We have shown that bacillus Calmette-Guerin
(BCG) infection suppresses the sensitivity of airway smooth
muscle, airway eosinophilic inflammation, and Th2 immune
response in our animal model of allergic asthma (6, 7). Recent-
ly, we have reported in our clinical trials (8, 9) that BCG
vaccination improves lung function and reduces medication
use in adult asthmatics.
BCG induces Mycobacterium-specific Th1 immune res-
ponse (5) and then may suppress allergen-specific Th2 immune
response which plays an important role in allergic asthma.
Additionally, it is reasonable to consider that the surround-
ing cytokine milieu secreted by BCG-infected dendritic cells
(DCs) enhances allergen-specific Th1 immune response and
suppresses allergen-specific Th2 immune response. DCs, the
major antigen-presenting cells, are host cell for mycobacteria
in vivo that trigger innate and acquired immunity (10). The
interaction of DCs with Mycobacterium tuberculosis or BCG
results in direct cell maturation and activation with produc-
tion of IL-12 (11, 12), which plays a major role in the induc-
tion and potentiation of IFN- in response to BCG. (13). Myco-
bacterium tuberculosis-infected DCs are also reported to secrete
IL-18 and IFN- , which play a significant role in enhancing
IFN- synthesis by T cells (14). Rather, DCs infection with
BCG may induce IL-10 production (11), which antagonizes
the effect of IL-12 (15).
Thus, the purpose of this study is to investigate that the
surrounding cytokine milieu secreted by BCG-treated DCs
directly enhances allergen-specific Th1 response and/or sup-
presses allergen-specific Th2 response in patients with Der-
matophagoides farinae-sensitive asthma.
MATERIALS AND METHODS
Subjects
Five patients with mild-to-moderate asthma were selected
on the basis of allergy to D. farinae, as indicated by a posi-
tive skin prick test response (wheal size >4 mm) and specif-
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Effects of Cytokine Milieu Secreted by BCG-treated Dendritic Cells
on Allergen-Specific Th Immune Response
Bacillus Calmette-Guerin (BCG) is reported to suppress Th2 response and asth-
matic reaction. Dendritic cells (DCs), the major antigen-presenting cells, infections
with BCG are known to result in inducing various cytokines. Thus, DCs are likely
to play a role in the effects of BCG on asthma. This study aims at investigating that
cytokine milieu secreted by BCG-treated DCs directly enhances allergen-specific
Th1 response and/or suppresses Th2 response in allergic asthma. DCs and CD3
+
T cells were generated from Dermatophagoides farinae-sensitive asthmatics. DCs
were cultured with and without BCG and subjected to flow cytometric analysis. IL-
12 and IL-10 were determined from the culture supernatants. Some DCs were
cocultured with T cells in the presence of D. farinae extracts after adding the cul-
ture supernatants from BCG-treated DCs, and IL-5 and IFN- were determined.
BCG-treated DCs enhanced significantly the expressions of CD80, CD86, and
CD40, and the productions of IL-12 and IL-10. Addition of culture supernatants
from BCG-treated DCs up-regulated production of IFN- by T cells stimulated by
DCs and D. farinae extracts (p<0.05), but did not down-regulate production of IL-5
(p>0.05). The cytokine milieu secreted by BCG-treated DCs directly enhanced
allergen-specific Th1 response, although did not suppress Th2 response.
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ic IgE to D. farinae (UniCAP >11 kU/L or Multiple Aller-
gen Simultaneous Test-Chemiluminescent Assays [MAST-
CLA] class=4). They visited the Allergy Clinic at Chonnam
University Hospital to get a medical certificate for current
status of their asthma before they enter the military. Their
mean age and asthma duration were 19.4 and 11.2 yr, respec-
tively. The asthmatic subjects met the definition of asthma
laid out by the American Thoracic Society (16). In order to
enhance the chance of being rejected they ceased taking anti-
asthmatic medications for some months prior to this study.
They inhaled only short-acting  2-agonist on demand as res-
cue medication. The  2-agonist was withheld during at least
an 8-hr period to the present study. We also included four
nonatopic control subjects who had no symptoms of allergy
or asthma. All subjects gave their informed written consent.
The study was approved by the Human Ethics Review Com-
mittee of our University Hospital.
Generation of DCs and T cells
Peripheral blood mononuclear cells (PBMCs) were isolat-
ed from freshly collected buffy coats by density gradient cen-
trifugation using a Lymphoprep (Nycomed, Oslo, Norway).
CD14+ cells were isolated from PBMCs using LS-MACS
column (Miltenyi Biotec, Auburn, CA, U.S.A.), in which
the purity of CD14+ cells was >95%. DCs were generated
by culturing the CD14+ cells in T-25 culture flasks (Nunc,
Roskilde, Denmark) with 50 ng/mL GM-CSF (LG Biochem-
ical, Daejeon, Korea) and 50 ng/mL IL-4 (R & D Systems,
Minneapolis, MN, U.S.A.) for 6 days at 1×106 cells/mL in
RPMI 1640 (BioWhittaker, Walkersville, MD, U.S.A.) sup-
plemented with 10% FBS (Gibco, Grand Island, NY, U.S.A.)
and antibiotics consisting of 100 U/mL penicillin, 100  g/mL
streptomycin, and 0.25  g/mL fungizone (BioWhittaker).
CD3+ T cells were isolated by human T cell enrichment co-
lumns (R & D Systems), in which the purity of CD3+ cells
was >90% and the T cells were stored in liquid nitrogen until
culture.
BCG treatment of DCs
Mycobacterium bovis BCG (French strain 1173P2) was pro-
duced at Korean National Tuberculosis Association in the
form of lyophilized powder. DCs (1×105) were treated for
40 hr with 1.5×105 colony forming units (CFUs) of BCG,
because it has been found that the addition of BCG over 3×
105 CFUs significantly influenced cell viability, whereas BCG
below 1×105 CFUs did not induce any change of DC phe-
notypes in a previous experiment by Kim et al. (12). Some
DCs were cultured without BCG treatment during the same
time. Some supernatants were stored at -70℃ for cytokine
assays of IL-12 and IL-10 and others were added to the fol-
lowing DC-T cell cocultures. DCs were subjected to the fol-
lowing flow cytometric analysis.
Flow cytometric analysis
For immunophenotyping, DCs were resuspended in RPMI
1640 (BioWhittaker) supplemented with 10% FBS (Gibco)
and incubated for 30 min at 4℃ with one of the following
mouse monoclonal antibodies: phycoerythrin (PE)-conjugat-
ed anti-HLA-DR; PE-conjugated anti-CD86; PE-conjugated
anti-CD54; PE-conjugated anti-CD11c; fluorescein isothio-
cyanate (FITC)-conjugated anti-CD80; FITC-conjugated anti-
CD83; FITC-conjugated anti-CD40, and FITC-conjugated
anti-CD1a (PharMingen, San Diego, CA). Mouse immunoglob-
ulin G1-PE/FITC isotype control (PharMingen) was used as
a control. The fluorescence was measured on a FACS Caliber
cell sorter (Becton Dickinson, San Jose, CA, U.S.A.) and ana-
lyzed with CellQuest software (Becton Dickinson).
T-DC cell cocultures
CD3+ T cells were thawed on the day of use. T cells (1×
105) were cocultured with irradiated (30 Gy) autologous DCs
at a ratio 10:1 for 6 days in the presence of crude protein
extracts of D. farinae (10  g/mL, Yonsei University College
of Medicine, Seoul, Korea). Control cultures were T cell alone
or T-DC cell cocultures. In order to investigate the effect of
the surrounding cytokine milieu secreted by BCG-treated
DCs on D. farinae-specific Th1 and Th2 immune responses,
100  L per well of the culture supernatants from BCG-treat-
ed DCs was added at the beginning of T-DC cell cocultures
in the presence of D. farinae extracts. Supernatants were col-
lected from the cultures on day 5 and stored at -70℃ for
cytokine assays of IL-5 and IFN- .
Proliferation assays
T cell proliferation during the last 18 hr of 6-day cultures
was quantified by [3H] thymidine uptake of cells incubated
with 1  Ci of [methyl-3H] thymidine (Amersham Pharma-
cia Biotech, Buckinghamshire, U.K.). The cells were har-
vested onto paper filters using a Titertek Cell Harvester 530
(Flow Laboratories, Irvine, U.K.) and the radioactivity was
measured using a Beckman LS 6500 multipurpose scintilla-
tion counter (Beckman Instruments, Fullerton, CA, U.S.A.).
Results are presented as mean counts per minute (cpm) of
triplicated cultures.
Cytokine assays
The concentrations of IL-12, IL-10 (R & D Systems), IL-5,
and IFN- (Endogen, Woburn, MA, U.S.A.) were determined
by using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits. The standard curves were generated
by the standards of known cytokine content provided. Sen-
sitivities were 0.5 pg/mL for IL-12, 3.9 pg/mL for IL-10, 2
pg/mL for IL-5, and 2 pg/mL for IFN- .642 Y. Koh, I. Choi, J.-J. Lee
Statistical analysis
Data were expressed as mean±SEM. The differences bet-
ween the two groups and within the same group were ana-
lyzed with the Mann-Whitney U test and the Wilcoxon’s
signed-rank test, respectively. A p<0.05 value was consid-
ered statistically significant.
RESULTS
DCs activation by BCG and IL-12 and IL-10 productions
by BCG-treated DCs
Activated DCs are known to express high levels of co-stim-
ulatory molecule and secrete inflammatory cytokines (17).
We tested the effect of BCG on DC activation. DCs from
asthmatics were cultured with or without BCG, and the cell-
surface marker expression was examined by flow cytometry
after staining with various antibodies. DCs cultured with
BCG showed a significant increase in expression of the co-
stimulatory molecules CD40 (p<0.05), CD80 (p<0.05), and
CD86 (p<0.05) compared with those cultured without BCG.
The expression of the MHC class II molecule HLA-DR (p=
0.08) and the DC-specific marker CD83 (p=0.08) tended to
increase in BCG-treated DCs compared with untreated
DCs (Fig. 1). These data suggests that BCG treatment is
sufficient to induce DCs to mature into an ‘activated’ phe-
notype.
In parallel, we tested the effect of BCG treatment on IL-
12 and IL-10 cytokine productions by DCs from asthmatics.
The quantities of IL-12 (p<0.05) and IL-10 (p<0.05) were
significantly higher in the culture supernatant from BCG-
treated DCs than in that from untreated DCs (Fig. 2).
T cell proliferation and IL-5 and IFN- productions by T
cells stimulated by DCs and D. farinae extracts
In asthmatics, T cell proliferations of T-DC cell cocultures
were significantly increased in the presence of D. farinae ex-
tracts compared with the absence of D. farinae extracts (p<
0.05, Fig. 3). In contrast, in nonatopic controls, T cell pro-
liferations of T-DC cell cocultures in the presence of D. fari-
nae extracts were similar to those in the absence of D. fari-
nae extracts (p>0.05, data not shown). This indicates that T
cell proliferation from asthmatics is induced by autologous
DCs in a pattern of D. farinae-specific response.
In parallel, we analyzed the cytokine pattern in the super-
natants from T-DC cell cocultures in the presence of D. fari-
nae extracts. IL-5 concentration was higher in asthmatics than
in nonatopic controls (325.2±87.2 pg/mL vs. 181.6±110.2
pg/mL, p=0.33), although not significant. However, IFN-
concentration in asthmatics was similar to that in nonatopic
controls (1,605.1±423.0 pg/mL vs. 1,509.4±574.1 pg/mL).
Up-regulation of D. farinae-specific IFN- production
after addition of culture supernatants from BCG-treated
DCs to T-DC cell cocultures
In order to test the effects of the cytokine milieu secreted
by BCG-treated DCs on D. farinae-specific Th1 and Th2
response in asthmatics, we analyzed the cytokine pattern in
the supernatants collected from T-DC cell cocultures in the
E
x
p
r
e
s
s
i
o
n
 
(
%
)
120
100
80
60
40
20
0
HLA-DR CD1a CD11c CD40 CD54 CD80 CD83 CD86
Surface antigen
Fig. 1. Comparisons of surface antigen expression between un-
treated DCs and BCG-treated DCs from asthmatics. Expression
represents the percentage of positive cells on FACS analysis after
staining with the corresponding antibodies. Data are expressed
mean±SEM. Statistical significance was determined by using
the Wilcoxon’s signed-rank test.
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Fig. 2. Comparisons of IL-12 (A) and IL-10 (B) productions between
untreated DCs and BCG-treated DCs from asthmatics. Statistical
significance was determined by using the Wilcoxon’s signed-rank
test.
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presence of D. farinae extracts after adding the culture super-
natants from BCG-treated DCs. The addition of the culture
supernatant from BCG-treated DCs significantly up-regu-
lated the production of IFN- by T cells, with IFN- levels
being 2,538.1±461.8 pg/mL and 1,605.1±423.0 pg/mL
in the presence or absence of the culture supernatant from
BCG-treated DC, respectively (p<0.05). On the other hand,
the addition of the culture supernatant from BCG-treated
DCs did not down-regulate the production of IL-5, with
IL-5 levels being 445.1±160.7 pg/mL and 325.2±87.2
pg/mL in the presence or absence of the culture supernatant
from BCG-treated DCs, respectively (Fig. 4). Additionally,
the addition of the culture supernatant from BCG-treated
DCs did not affect T cell proliferation of T-DC cell cocultures
in the presence of D. farinae extracts (Fig. 3). 
DISCUSSION
In the present study, the production of IFN- from T cells
stimulated by DCs and D. farinae extracts was increased fol-
lowing the addition of the culture supernatant obtained from
BCG-treated DCs in D. farinae-sensitive asthmatics, while
IL-5 production was not decreased. This finding suggested
that the surrounding cytokine milieu secreted by BCG-treat-
ed DCs directly enhanced allergen-specific Th1 response,
although did not suppress allergen-specific Th2 response.
The present study showed that BCG treatment induced
the maturation and activation of DCs and the production of
IL-12 from DCs. The production of IL-12, which is thought
to be a prime initiator of Th1 response (18), may contribute
mainly to the direct enhancement of allergen-specific Th1
response in our study. Additionally, DC infection with Myco-
bacterium tuberculosis or BCG results in inducing another cyto-
kines, such as IL-1 (11), IL-10 (11), IL-18 (14), TNF- (11,
12), and IFN- (14). IL-18 and IFN- have been also report-
ed to have a significant role in enhancing Th1 response by
inducing T cell IFN- production and the expression of Th1-
type cytokine receptors (14, 19). IL-18 and IFN- are likely
to contribute to the direct enhancement of allergen-specific
Th1 response, although they were not determined in our
study. We also found that the production of IL-10 by BCG-
treated DCs was enhanced. Because IL-10 may inhibit T cell
IFN- production by suppressing IL-12 synthesis (15), the
enhancing effect of IL-12, IL-18, and IFN- on allergen-spe-
cific Th1 response could be down-regulated by IL-10. How-
ever, this is not the case in our study, suggesting that a dyna-
mic interplay among the various cytokines is responsible for
net IFN- production.
It is well known that Th1 and Th2 cells reciprocally reg-
ulate each other through the cytokines they secrete (1, 2). It
is possible that the allergen-specific Th1 cytokine enhanced
by the cytokine milieu secreted by BCG-treated DCs may
suppress the production of allergen-specific Th2 cytokine,
which is instrumental in initiating and sustaining the aller-
gic inflammation in asthma. IL-4 down-modulates the expres-
sion of the IL-12R  chain on T cells. This down-modula-
tion leads to the generation of Th2 cells, since they are no
longer responsive to IL-12-mediated signaling (20). How-
ever, the presence of IFN- may inhibit this IL-4-induced
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Fig. 3. Comparisons of T cell proliferations among T cell alone (T),
T-DC coculture (T/DC), T-DC coculture in the presence of D. fari-
nae extracts (T/DC/Df), and T-DC coculture in the presence of D.
farinae extracts after adding the culture supernatant from BCG-
treated DC (T/DC/Df/Supernatant) in D. farinae-sensitive asthmat-
ics. Statistical significance was determined by using the Wilcox-
on’s signed-rank test.
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effect. Therefore, allergen-specific Th2 memory cells may
produce Th1 cytokines when activated in the presence of
IL-12, a potent IFN- -inducing protein (21), before the more
malleable resting memory T cells differentiate into end-stage
effector cells (22) in which Th2 effector cells lose IL-12 recep-
tor function (23). However, the enhanced allergen-specific
Th1 response failed to do that in this in vitro study. One of
the possible explanations can be that the polarized memory
and/or end-stage effector allergen-specific Th2 cells might
have lost the expression of functional IL-12 receptors. This
can be supported by a recent study (24) showing that the
cytokine profile of allergen-specific Th2 cells from atopic
individuals is not inhibited when the allergen is presented
by DCs in the presence of exogenous recombinant human
IL-12. Another can be that the allergen-specific Th1 cytokine
enhanced directly by the cytokine milieu secreted by BCG-
treated DCs is not sufficient to suppress the allergen-specific
Th2 response. Indeed, Mycobacterium species induce potent
Mycobacterium-specific Th1 response (4, 5), which may also
contribute to the inhibition of allergen-specific Th2 respons-
es. Therefore, it is more probable that the administration of
BCG in vivo suppresses the allergen-specific Th2 response,
via both the allergen-specific Th1 response by the cytokine
milieu secreted by BCG-infected DC and the Mycobacterium-
specific Th1 response.
Recently, Arkwright and David (25) have reported that
intradermal administration of a killed Mycobacterium vaccae
suspension is associated with improvement in the severity
of the atopic dermatitis in children. We have also reported
in two successive clinical trials (8, 9) that single or repeated
BCG vaccinations improve lung functions in asthmatics,
being indicative of the therapeutic effects of BCG on asthma.
Based on the data from the present in vitro study, it may be
inferred that IFN- production from T cells enhanced by the
surrounding cytokine milieu produced by BCG-infected DC
contributes to the increased lung function. It has been report-
ed that IFN- can induce nitric oxide production (26), which
causes dilatation of the airway smooth muscle in patients
with allergic asthma and reverses bronchoconstriction (27,
28) and also reduces airway hyperresponsiveness (28, 29).
We have also shown that the change in IFN- produced by
peripheral blood T cells has a positive relationship with the
change in morning peak expiratory flow rate in asthmatics
(30). However, as mentioned above, it is possible that strong
Th1 response generated in vivo by both the cytokine milieu
secreted by BCG-infected DCs and the Mycobacterium-spe-
cific T cell response may suppress Th2 response and then
improve lung function. Besides, IL-10 from BCG-treated
DCs may also contribute to the therapeutic effects of BCG
on asthma. Although IL-10 is known to inhibit Th1 response
(15), IL-10 therapy might alleviate allergic inflammation by
inhibiting different steps involved in the accumulation of
eosinophils into target tissues and be useful in controlling asth-
ma (31). Recently, Zuany-Amorim et al. (32) have demon-
strated that regulatory T cells generated by mycobacteria
treatment may inhibit the allergic inflammation, suggesting
that mechanism other than simple changes in the balance
between Th1 and Th2 response may be responsible for the
effect of BCG treatment on asthma. Because IL-10 produc-
tion by DCs has been reported to develop the regulatory T
cells (33), IL-10 from BCG-treated DC might induce the
regulatory T cells in the present study, for which a further
investigation is needed.
In the present study, although the concentration of IL-5
in supernatants from T-DC cell cocultures stimulated by D.
farinae extracts was higher in asthmatics than in nonatopics,
the significant Th2 cytokine profile was not observed in asth-
matics. It is possible that T cell stimulation may not suffi-
cient to induce the significant Th2 profile. Indeed, no more
stimulation was used in our study, while T cells were restimu-
lated twice more with newly generated allergen-pulsed DCs
in a study of Bellinghausen et al. (34) showing that the sig-
nificant Th2 cytokine profile was induced in T helper cells
from atopics after stimulation with autologous allergen-pulsed
DCs.
An endotoxin or unknown mitogen-like factor contami-
nation of the D. farinae extracts or the culture supernatant
from BCG-treated DCs is likely to affect the D. farinae-spe-
cific Th1 and Th2 immune response, although the factors
were not determined in the present study. However, our find-
ing that T cell proliferation of T-DC cell cocultures did not
differ according to the presence or absence of D. farinae extracts
in nonatopic controls might indicate that the factors were
unlikely to be contained in the D. farinae extracts. Also, it
was unlikely that the factors were contained in the culture
supernatant based on our observation that the addition of
the culture supernatant from BCG-treated DCs did not affect
T cell proliferation of T-DC cell cocultures in the presence
of D. farinae extracts, as shown in Fig. 3. Additionally, the
possible reason for the observation might be the counterbal-
ance effect of IL-12 and IL-10 in the culture supernatant on
allergen-specific T cell proliferation. It has been demonstrat-
ed that IL-12 enhances allergen-specific T cell proliferation
(21) but IL-10 inhibits the T cell proliferation (35).
In summary, the surrounding cytokine milieu secreted by
BCG-treated DCs may directly enhance allergen-specific Th1
immune response in allergic asthma, which may be one of
the various mechanisms of beneficial effects of BCG on asth-
ma. Furthermore, the present study may provide a potential
basis for an immunomodulation therapy using BCG-treated
DC as a new treatment of asthma.
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